A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
Saved in:
| Title: | A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. |
|---|---|
| Authors: | Eriksen, Martina1,2 (AUTHOR) martina.amnitzboell.eriksen@regionh.dk, Pfeiffer, Per3 (AUTHOR), Rohrberg, Kristoffer Staal1 (AUTHOR), Yde, Christina Westmose4 (AUTHOR), Petersen, Lone Nørgård1 (AUTHOR), Poulsen, Laurids Østergaard5 (AUTHOR), Qvortrup, Camilla1,2 (AUTHOR) |
| Source: | BMC Cancer. 12/19/2022, Vol. 22 Issue 1, p1-6. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14712407 |
|---|---|
| DOI: | 10.1186/s12885-022-10420-x |
